Boston, July 12, 2022 – TransCellular Therapeutics (TCT), a biotech focused on the development of enzyme replacement therapy, and the Barth Syndrome Foundation (BSF) proudly announce an investment partnership to advance this targeted treatment for the 250+ individuals affected by Barth syndrome worldwide.
Building upon research first conducted at the University of Washington...